Gemifloxacin

Gemifloxacin

SCHEMBL2421087

CON=C1CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)C[C@H]1CN.CS(=O)(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

gyrAgyrBparCparE

The experimentally established mechanism targets of Gemifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 1.00
KDM4E B2RXH2 2/20 1.00
HSD17B10 Q99714 2/20 1.00
ABCC4 O15439 1/20 1.00
DPP4 P27487 6/20 0.93
CHRM2 P08172 1/20 0.93
DRD1 P21728 1/20 0.93
ALDH1A1 P00352 1/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
XBP1 P17861 1/20 0.47
NFKB1 P19838 1/20 0.47
HTT P42858 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
KCNH2 Q12809 1/20 0.44
DHFR P00374 1/20 0.43
CYP2C9 P11712 1/20 0.40
ATP6V1B2 P21281 1/20 0.40
TBXA2R P21731 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gemifloxacin SCHEMBL136827 1.00 LMNA (1.00) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL2421086 1.00 LMNA (1.00) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL3141327 1.00 LMNA (1.00) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL1237121 1.00 LMNA (1.00) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL29408809 1.00 LMNA (1.00) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL5661711 0.99 LMNA (0.98) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL5661708 0.99 LMNA (0.98) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL3281156 0.99 LMNA (0.98) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL3281159 0.99 LMNA (0.98) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL5658681 0.99 LMNA (0.98) LMNAKDM4EHSD17B10ABCC4DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1603875-B1 NEW PROCESS FOR PREPARING 4-AMINOMETHYL-3-ALKOXYIMINOPYRROLIDINE METHANESULFONATE LG LIFE SCIENCES LTD (KR) 2011-09-21 EP claimed
US-7687629-B2 Process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate LG LIFE SCIENCES LTD. (KR) 2010-03-30 US claimed
EP-1603875-A4 NEW PROCESS FOR PREPARING 4-AMINOMETHYL-3-ALKOXYIMINOPYRROLIDINE METHANESULFONATE LG LIFE SCIENCES LTD (KR) 2008-11-19 EP claimed
EP-1412078-B1 PROCESSES FOR THE PRODUCTION OF AMINO-PROTECTED DERIVATIVES OF 4-AMINOMETHYLENE-PYRROLIDIN-3-ONE, GEMIFLOXACIN OR A SALT THEREOF LG LIFE SCIENCES LTD (KR) 2008-10-08 EP claimed
US-20070282107-A1 New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate LG LIFE SCIENCES LTD. 2007-12-06 US claimed
US-7232907-B2 Process for production of naphthyridine-3-carboxylic acid derivatives LG LIFE SCIENCES LIMITED (KR) 2007-06-19 US claimed
US-7199242-B2 Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof LG LIFE SCIENCES LIMITED (KR) 2007-04-03 US claimed
US-20060173195-A1 Process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate LG CHEM, LTD. (KR) 2006-08-03 US claimed
EP-1603875-A1 NEW PROCESS FOR PREPARING 4-AMINOMETHYL-3-ALKOXYIMINOPYRROLIDINE METHANESULFONATE LG Life Sciences Ltd (KR) 2005-12-14 EP claimed
US-20050176961-A1 Process for production of naphthyridine-3-carboxylic acid derivatives SB PHARMCO PUERTO RICO INC. 2005-08-11 US claimed
EP-1068182-B1 PROCESS FOR PREPARING A PROTECTED 4-AMINOMETHYL-PYRROLIDIN-3-ONE LG LIFE SCIENCES LTD (KR) 2005-06-08 EP claimed
US-20050043546-A1 Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof LG CHEM, LTD. (KR) 2005-02-24 US claimed
WO-2004092129-A1 NEW PROCESS FOR PREPARING 4-AMINOMETHYL-3-ALKOXYIMINOPYRROLIDINE METHANESULFONATE LG LIFE SCIENCES LTD. (KR) 2004-10-28 WO claimed
US-6803467-B2 ANTIBACTERIAL ACTIVITY LG LIFE SCIENCES LIMITED (KR) 2004-10-12 US claimed
US-20040138292-A1 Intermediates for the production of quinolone carboxylic acid derivatives SB Pharmco Puerto Rico Inc of the United States Corporation Company. 2004-07-15 US claimed
EP-1214321-B1 PROCESS FOR PRODUCTION OF NAPHTHYRIDINE-3-CARBOXYLIC ACID DERIVATIVES LG LIFE SCIENCES LTD (KR) 2004-07-14 EP claimed
EP-1212321-B1 INTERMEDIATES FOR THE PRODUCTION OF NAPHTHYRIDINE-3-CARBOXYLIC ACID DERIVATIVES LG LIFE SCIENCES LTD (KR) 2004-07-07 EP claimed
EP-1412078-A1 PROCESSES FOR THE PRODUCTION OF AMINO-PROTECTED DERIVATIVES OF 4-AMINOMETHYLENE-PYRROLIDIN-3-ONE AND/OR 4-AMINOMETHYLENE-PYRROLIDIN-3-ALKOXYIMINO DERIVATIVES AND/OR GEMIFLOXACIN OR A SALT THEREOF SB Pharmco Puerto Rico Inc (US) 2004-04-28 EP claimed
WO-2003011450-A1 PROCESSES FOR THE PRODUCTION OF AMINO-PROTECTED DERIVATIVES OF 4-AMINOMETHYLENE-PYRROLIDIN-3-ONE AND/OR 4-AMINOMETHYLENE-PYRROLIDIN-3-ALKOXYIMINO DERIVATIVES AND/OR GEMIFLOXACIN OR A SALT THEREOF LG LIFE SCIENCES LIMITED (KR) 2003-02-13 WO claimed
US-6307059-B1 PREPARATION OF QUINOLONE ANTIBIOTICS. LG CHEMICAL, LTD (KR) 2001-10-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043546-A1 Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof CYP4X1, PM20D2, BRIX1 LMNA 3130/4885KDM4E 551/4885HSD17B10 4114/4885
US-20070282107-A1 New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate MLN, AAAS, ACMSD LMNA 1610/4885KDM4E 333/4885HSD17B10 3607/4885
US-20050176961-A1 Process for production of naphthyridine-3-carboxylic acid derivatives NRDC, NDC1, NQO2 LMNA 1345/4885KDM4E 3931/4885HSD17B10 693/4885
US-20060173195-A1 Process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate MLN, ACMSD, AAAS LMNA 1474/4885KDM4E 249/4885HSD17B10 3782/4885
US-20040138292-A1 Intermediates for the production of quinolone carboxylic acid derivatives NQO2, COASY, SDHA LMNA 3607/4885KDM4E 3173/4885HSD17B10 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.